{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sahu R"],"funding":["University Grants Commission","University Grants Commission (University Grants Commission India)"],"pagination":["2207-2219"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9726943"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["127(12)"],"pubmed_abstract":["<h4>Background</h4>Mammary carcinogenesis possesses great challenges due to the lack of effectiveness of the multiple therapeutic options available. Gene therapy-based cancer treatment strategy provides more targeting accuracy, fewer side effects, and higher therapeutic efficiency. Downregulation of the oncogene mTOR by mTOR-siRNA is an encouraging approach to reduce cancer progression. However, its employment as means of therapeutic strategy has been restricted due to the unavailability of a suitable delivery system.<h4>Methods</h4>A suitable nanocarrier system made up of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) has been developed to prevent degradation and for proficient delivery of siRNA. This was followed by in vitro and in vivo anti-breast cancer efficiency analysis of the"],"journal":["British journal of cancer"],"pubmed_title":["Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis."],"pmcid":["PMC9726943"],"funding_grant_id":["201819-NFO-2018-19-OBC-ORI-80495"],"pubmed_authors":["Jha S","Pattanayak SP","Sahu R"],"additional_accession":[]},"is_claimable":false,"name":"Therapeutic silencing of mTOR by systemically administered siRNA-loaded neutral liposomal nanoparticles inhibits DMBA-induced mammary carcinogenesis.","description":"<h4>Background</h4>Mammary carcinogenesis possesses great challenges due to the lack of effectiveness of the multiple therapeutic options available. Gene therapy-based cancer treatment strategy provides more targeting accuracy, fewer side effects, and higher therapeutic efficiency. Downregulation of the oncogene mTOR by mTOR-siRNA is an encouraging approach to reduce cancer progression. However, its employment as means of therapeutic strategy has been restricted due to the unavailability of a suitable delivery system.<h4>Methods</h4>A suitable nanocarrier system made up of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) has been developed to prevent degradation and for proficient delivery of siRNA. This was followed by in vitro and in vivo anti-breast cancer efficiency analysis of the","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-22T17:27:54.531Z","creation":"2025-04-06T02:07:50.505Z"},"accession":"S-EPMC9726943","cross_references":{"pubmed":["36261586"],"doi":["10.1038/s41416-022-02011-1"]}}